Skip to main content

Srikripa Devarakonda

Stock Analyst at Truist Financial

Total Price Targets
15
Stocks Covered
11
Sectors
Healthcare
Most Recent
Apr 14, 2026

Notable Calls (Last 12 Months)

Most Bullish

  • MBX+73.7%
    MBX Biosciences, Inc. Common Stock
    $50.00 targetMar 9, 2026
  • ARVN+44.2%
    Arvinas, Inc.
    $11.00 targetMay 5, 2025
  • CYTK+38.4%
    Cytokinetics, Incorporated
    $92.00 targetFeb 3, 2026

Most Bearish

  • ARVN-8.8%
    Arvinas, Inc.
    $10.00 targetMar 18, 2026
  • INCY+2.1%
    Incyte Corporation
    $103.00 targetDec 24, 2025
  • LLY+12.6%
    Eli Lilly and Company
    $1182.00 targetNov 19, 2025

Stocks Covered by Srikripa Devarakonda

SymbolCompanyLatest TargetCurrent PriceUpside# TargetsLast Updated
PTGXProtagonist Therapeutics, Inc.$121.00$98.16+23.3%3Apr 14, 2026
ARVNArvinas, Inc.$10.00$10.55-5.2%2Mar 18, 2026
MBXMBX Biosciences, Inc. Common Stock$50.00$30.09+66.2%1Mar 9, 2026
SRRKScholar Rock Holding Corporation$55.00$46.75+17.6%1Mar 3, 2026
CYTKCytokinetics, Incorporated$92.00$64.40+42.9%2Feb 3, 2026
INCYIncyte Corporation$103.00$96.41+6.8%1Dec 24, 2025
KYMRKymera Therapeutics, Inc.$116.00$81.54+42.3%1Dec 9, 2025
BMYBristol-Myers Squibb Company$65.00$58.22+11.6%1Dec 3, 2025
LLYEli Lilly and Company$1182.00$961.67+22.9%1Nov 19, 2025
EWTXEdgewise Therapeutics, Inc.$50.00$30.63+63.2%1Dec 5, 2024
KROSKeros Therapeutics, Inc.$100.00$11.48+771.1%1Nov 5, 2024

Recent Activity

  • Apr 14, 2026— Set$121.00price target onPTGX(Protagonist Therapeutics, Inc.)
  • Mar 18, 2026— Set$10.00price target onARVN(Arvinas, Inc.)
  • Mar 9, 2026— Set$50.00price target onMBX(MBX Biosciences, Inc. Common Stock)
  • Mar 3, 2026— Set$55.00price target onSRRK(Scholar Rock Holding Corporation)
  • Feb 3, 2026— Set$92.00price target onCYTK(Cytokinetics, Incorporated)
  • Dec 24, 2025— Set$103.00price target onINCY(Incyte Corporation)
  • Dec 22, 2025— Set$84.00price target onCYTK(Cytokinetics, Incorporated)
  • Dec 9, 2025— Set$116.00price target onKYMR(Kymera Therapeutics, Inc.)
  • Dec 3, 2025— Set$65.00price target onBMY(Bristol-Myers Squibb Company)
  • Nov 19, 2025— Set$1182.00price target onLLY(Eli Lilly and Company)
  • Oct 28, 2025— Set$88.00price target onPTGX(Protagonist Therapeutics, Inc.)
  • May 5, 2025— Set$11.00price target onARVN(Arvinas, Inc.)
  • Dec 5, 2024— Set$50.00price target onEWTX(Edgewise Therapeutics, Inc.)
  • Nov 22, 2024— Set$60.00price target onPTGX(Protagonist Therapeutics, Inc.)
  • Nov 5, 2024— Set$100.00price target onKROS(Keros Therapeutics, Inc.)

Frequently Asked Questions

Who is Srikripa Devarakonda?

Srikripa Devarakonda is a stock analyst at Truist Financial covering 11 stocks primarily in Healthcare. They have issued 15 price targets since Nov 5, 2024.

What stocks does Srikripa Devarakonda cover?

Srikripa Devarakonda currently covers 11 stocks, including PTGX, ARVN, CYTK, MBX, SRRK.

What is Srikripa Devarakonda's latest price target?

Srikripa Devarakonda's most recent price target was $121.00 on PTGX (Protagonist Therapeutics, Inc.), set on Apr 14, 2026.

What is Srikripa Devarakonda's highest price target?

Srikripa Devarakonda's highest issued price target is $1182.00 on LLY, set on Nov 19, 2025.

Coverage based on publicly published price targets. Not investment advice.